Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Oct 3.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2025 Apr 3;34(4):527–533. doi: 10.1158/1055-9965.EPI-24-1399

The Changing pathogenesis of liver cancer in Hawaii over three decades

Linda L Wong 1,2, Larry R Hromalik 1, Brenda Y Hernandez 2, Jared D Acoba 2,3, Sandi A Kwee 2,4
PMCID: PMC11968224  NIHMSID: NIHMS2053772  PMID: 39869025

Abstract

Background:

Worldwide trends support the increasing contribution of hepatic steatosis on the incidence of hepatocellular carcinoma (HCC). This study investigates if similar changes are seen in Hawaii, where the incidence of HCC is higher than most of the United States.

Methods;

This is a retrospective study of 1651 patients diagnosed with HCC (1991–2023) that includes 60–70% of Hawaii’s HCC cases. We evaluated changes in patient demographics, risk factors, and disease etiology over the three decades.

Results:

From 1991–2023, there were significant increases in the proportion of HCC cases attributable to metabolic-associated steatotic liver disease(MASLD), coinciding with a rise in the prevalence of metabolic risk factors including obesity, diabetes, hyperlipidemia, and hypertension. Cases with a history of smoking also increased through 2020. Conversely, HCC cases presenting with cirrhosis alone decreased. HCV-associated cases increased through 2015 and then tapered, while HBV-associated cases decreased through 2020. There was no significant change in the proportion of alcohol-associated cases.

Conclusions:

While HBV continues to be a major contributor to HCC in Hawaii, HCV-related HCC cases have tapered, while metabolic risk factors for HCC and cases attributable to MASLD have increased over time, parallelling overall trends observed in the United States. Efforts are needed to manage these metabolic factors to address the burden of HCC.

Impact;

Although Hawaii continues to have a large burden of viral hepatitis related HCC, metabolic factors and MASLD have affected the pathogenesis of liver cancer in Hawaii over the past the past 3 decades.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and the third most frequent cause of cancer death. In 2020, HCC was diagnosed in over 900,000 people and was responsible for an estimated 830,000 deaths. (1) While the incidence of HCC in the US is low relative to Asian countries, HCC was one of the few cancers that increased in incidence in the US until 2015 when rates stabilized at 9.6 new cases of HCC per 100,000 population. (2)

The major risk factor for HCC is the presence of an underlying cirrhosis or chronic liver disease primarily due to hepatitis B, hepatitis C, alcohol-related liver disease and metabolic associated steatotic liver disease (MASLD). Patients with other less common chronic liver diseases like autoimmune hepatitis, hemochromatosis, primary sclerosing cholangitis and primary biliary cirrhosis are also at risk for development of HCC. Geographic differences in HCC incidence are likely related to the variable prevalence of these risk factors as well as the contributing factors of obesity, diabetes, hyperlipidemia and smoking. (3)

Historically in Hawaii, HCC incidence was among the highest in the US, likely the result of the large population of Asian and Pacific Islanders, many of whom had immigrated from Asian countries where hepatitis B is endemic. We previously published studies that investigated specific ethnic populations in Hawaii with a high burden of HCC with most of these demonstrating a strong relationship to chronic hepatitis B. (4–9) However, in recent years, Hawaii maintained a relatively stable incidence of HCC while several US states have had a rapid increase in HCC. The factors that may have contributed to this recent trend include the decrease in hepatitis B related HCC in Hawaii as well as the relative increase in MASLD, which is known to have substantially impacted other parts of the US. This study aims to take a deeper look at the epidemiology, etiology and factors that have contributed to the burden of HCC in Hawaii.

Materials and Methods

This is a retrospective study of 1651 patients diagnosed with HCC over a 30-year period (1993–2022) from Hawaii’s only liver transplant and liver disease centers in the state. This center also served as a tertiary referral center for the U.S. Affiliated Pacific Islands-- including the territories of American Samoa, Guam, Saipan, and the Commonwealth of the Northern Mariana Islands, and the Republic of Palau, the Republic of the Marshall Islands, and the Federated States of Micronesia-- as well as the Kingdom of Tonga. Patients also included foreign nationals from Asian countries who sought medical care in the US. The liver center and transplant center were affiliated with two urban medical centers in Honolulu, the largest city and metropolitan area in Hawaii: St. Francis Medical Center (later renamed Hawaii Medical Center-East) from 1993 to 2012 and The Queens Medical Center after 2012. Overall, these centers cared for approximately 60–70% of the HCC cases in Hawaii and this registry-based observational study includes all patients referred to these centers during this timeframe. This observational study was approved by the Institutional Review Board of the University of Hawaii at Manoa. All cases of HCC were included and there were no inclusion or exclusion criteria. This study utilized only deidentified data and was exempt for requiring patient consent.

HCC was diagnosed histologically by percutaneous biopsy or surgery, or more recently, if they met imaging criteria. In the first decade and consistent with the previous United Network for Organ Sharing (UNOS) policy regarding transplant for HCC, patients without histologic diagnosis of HCC were diagnosed non-histopathologically based on satisfying several criteria: a history of chronic liver disease, a mass of at least 2 cm seen on two imaging studies (ultrasound, CT scan or MRI), and one of the following: (1) vascular blush evident on CT scan or MRI, (2) alpha fetoprotein (AFP) > 200 ng/ml or (3) arteriogram confirming the tumor. Since 2011, the diagnosis of HCC was made with imaging alone if a contrast-enhanced study (triple phase CT or MRI) showed was designated at LI-RADS 5 (Liver Reporting and Data System) arterial enhancement with “washout” in the venous phase, enhancing capsular appearances, size at least 1 cm and threshold growth by 50% or more in 6 months. (10, 11)

Data collected:

Demographics, medical history, laboratory data, tumor characteristics, treatment, and survival were collected from clinical records. Demographic data specifically included age, biologic sex, birthplace, and the patient’s self-reported race was categorized as “White”, “Asian” (East Asians, including Filipinos), “Native Hawaiian/Other Pacific Islander (NHOPI)”, “Hispanic or Latino”, “Mixed”, or “Other (including Black, American Indian/Alaska Native” We further delineated subgroups of Asians into one of the following: Chinese, Japanese, Korean, Filipino, Southeast Asian and Other.

Sociodemographic information recorded included medical insurance type categorized into “Public” insurance (Medicare, Medicaid, Veterans Association), Private insurance, or uninsured, as well as how many years of formal education categorized into “finished high school” (≥ 13 years) versus not completing high school (< 13 years).

Medical history recorded included diabetes mellitus, hyperlipidemia, previous malignancy other than HCC, cigarette smoking, and risk factors for HCC including viral hepatitis, significant alcohol use (defined as greater than two alcoholic beverages daily for ≥ 10 years), and other chronic liver diseases. We collected information on recorded height and weight and determined body mass index (BMI). For this study, we have defined 4 categories based on BMI: underweight (BMI <18.5), normal (BMI 18.5 to 29.9), Obese (BMI 30–35) and Morbidly obese (BMI 35 or higher)

The collected laboratory data included bilirubin, albumin, prothrombin time with International Normalized Ratio (INR), creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelet count, and AFP level. Hepatitis B and C serologies were obtained if this information was not available from pre-existing records. For hepatitis B, we also noted patients who had only hepatitis B core antibody positivity in the absence of hepatitis B surface antigen. Data recorded included only anti-Hepatitis C antibody as information on viral levels and treatment responses were not consistently available. Laboratory data that were used for the study had been obtained within 2 weeks of an initial visit or at the time of the visit.. Normal AFP was defined as < 20 ng/dL.

Clinical criteria defining MASLD—such as steatotic liver disease, impaired glucose metabolism, hypertension, elevated triglyceride, low high density cholesterol (12)-- were not consistently available for all patients. Therefore, for the purpose of this study, MASLD was defined as a potential risk factor based on having documented diabetes, hyperlipidemia, or obesity in the absence of viral hepatitis B or C, significant alcohol use or any other known chronic liver disease.

Our Liver Center recommends HCC surveillance in patients with cirrhosis with AFP and liver ultrasound every six months as per the American Association for the Study of Liver Disease (AASLD) guidelines. (10) However, there was no uniform HCC screening protocol used throughout our community, although many primary care physicians with practices that included a large number of Asians used AFP testing and/or imaging (ultrasound, CT scan or MRI) at variable intervals. HCC was deemed to be found on “surveillance” if the patient had a previous imaging study from three to twelve months prior to the current study. HCC not found on screening was either diagnosed following presentation of symptoms (pain, abdominal mass, weight loss, jaundice) or incidentally due to imaging done for unrelated reasons.

Statistical Analysis:

All analyses were performed using Excel and SPSS statistical software (IBM, version 27). The three decades of cohort follow-up were divided into 6 eras, each of which were 5 year intervals. Because this was a retrospective study, there was no need for randomization, blinding or power analysis. Changes in patient characteristics and disease etiology over calendar time were evaluated using Cochran-Mantel-Haenszel tests (categorical variables) or generalized linear models (continuous variables). Kaplan-Meier survival was calculated by era. Cox regression was used to determine if the following factors affected survival, age, sex, era, diabetes, hyperlipidemia, obesity, Hepatitis B, Hepatitis C, alcohol, smoking, cirrhosis, MASLD, AJCC stage and undergoing liver transplant.

Data Availability

The data generated in this study are not publicly available as information could compromise patient privacy as it contains sensitive information and coming from a small area. However portions of the data that do not include specific dates or protected health information can be available upon reasonable request from the corresponding author.

Results

The cohort was comprised of 1651 patients with a mean age of 64.0 years (SD 11.2); 74.7% were male. Asians were the largest racial group (56.1%), followed by Whites (21.3%), NHOPI, 15.7%), Mixed race (4.1%), Hispanic (2.2%), Black (0.6%), American Indian (0.1%). The prevalence of risk factors was as follows: 24.8% were hepatitis B surface Ag positive (10.9% were core Ab positive), 39.5% were hepatitis C positive, 42.5% had significant alcohol use, and 61.1 % had a history of smoking. In terms of metabolic risk factors; 15% had MASLD, 36.9% had diabetes, 30% had hyperlipidemia, 52.2% had hypertension. Obesity was noted in 22% with overall mean BMI 27.2 (SD 7.8).

HCC patients presented at older ages with 38.5% age 70 years or older in the most recent time period. There continues to be a male predominance throughout the 3 decades and this has not changed. In terms of ethnicity and birthplace, there are also trends that are evident over the succeeding 6 eras. While Asians comprised over 70% of cases in earlier time periods, they now comprise approximately half of all HCC cases. An increasing proportion of the HCC cases have occurred in Whites and NHOPI. (Table 1) Furthermore, there has also been an increase in the proportion of cases occurring in Hispanics and those of mixed race. (Figure 1) The effect of immigrant status has also changed over the years. In the first era, birthplace was not well tracked however, in subsequent eras, there appears to be an increasing proportion of patients who were born in the US. While the number of actual cases of Asia- born HCC patients has not changed, the proportion is smaller. (Table 2)

Table 1.

Demographics, risk factors listed by 5 year eras.

Era 1
(1993–1997)
Era 2
(1998–2002)
Era 3
(2003–2007)
Era 4
(2008–2012)
Era 5
(2013–2017)
Era 6
(2018–2022)
P valueb

#patients 85 159 234 341 448 384
Mean Age (SD) 62.4 (12.8) 60.0(11.8) 61.3(12) 62.6(11.0) 65.2 (10.6) 67.3 (9.6) <0.0001
Age < 45 years 8 (9.4%) 15 (9.4%) 14 (6.0%) 10 (2.9%) 9 (2.0%) 6 (1.6%) <0.0001
Age 45–54 years 18 (21.2%) 38 (23.9%) 62 (26.5%) 68 (19.9%) 50 (11.2%) 28 (7.3%)
Age 55–64 years 18 (21.2%) 50 (31.4%) 65 (27.8%) 129 (37.8%) 174 (38.8%) 110 (28.7%)
Age 65–74 years 25 (29.4%) 33 (20.8%) 58 (24.8%) 75 (22%) 123 (27.5%) 154 (40.2%)
Age >74 years 16 (18.8%) 23 (14.5%) 35 (15.0%) 59 (17.3%) 92 (20.5%) 85 (22.2%)
Males 57 (67.1) 115 (72.3) 187 (79.9) 256 (75.1) 328 (73.2) 290 (75.5) 0.3291
Hepatitis B surfAg + 36 (42.4) 61 (38.4) 67 (28.6) 95 (27.9) 68 (15.2) 82 (21.4) <0.0001
Hepatitis B core Ab + 6 (7.1) 5 (3.1) 28 (12) 38 (11.1) 60 (13.4) 43 (11.2) <0.0001
Hepatitis C 23 (27.1) 51 (32.1) 100 (42.7) 135 (39.9) 208 (46.4) 134 (34.9) 0.0003
Alcohol 30 (35.3) 61 (38.4) 108 (46.2) 151 (44.3) 193 (43.1) 159 (41.4) 0.4988
MAFLD 3(3.5) 14(8.8) 13(5.6) 42 (12.3) 68 (15.2) 110 (28.6) <0.0001
Smoking 30 (35.3) 81 (50.9) 140 (59.8) 214 (62.6) 299 (66.7) 244 (63.5) <0.0001
Diabetes 28 (32.9) 41 (25.8) 59 (25.2) 120 (35.2) 190 (42.4) 171 (44.5) <0.0001
Hyperlipidemia 5(5.9) 15(9.4) 42 (17.9) 88(25.8) 150 (33.5) 195 (50.8) <0.0001
Hypertension 1 (1.2) 34 (21.4) 100 (42.7) 199 (58.4) 279 (62.3) 248 (64.6) 0.0056

Abbreviations; SD, Standard deviation, BMI, body mass index

a

all characteristics listed as number (%) except age and mean BMI

b

Cochran-Mantel-Haenszel tests or generalized linear models

Figure 1. Distribution of ethnicity by Era.

Figure 1

Patients with hepatocellular carcinoma have a changing distribution of ethnicity over time and succeeding 5 year eras

Table 2.

Ethnic distribution, birthplace, sociodemographics by era

Era 1
(1993–1997)
Era 2
(1998–2002)
Era 3
(2003–2007)
Era 4
(2008–2012)
Era 5
(2013–2017)
Era 6
(2018–2022)

#patients 85 159 234 341 448 384
Ethnicity
 Asian 65(76.5) 117(73.6) 148(63.2) 187(54.8) 228 (50.9) 181 (47.1%
  Chinese 12 24 31 35 39 45
  Filipino 11 24 38 47 57 43
  Japanese 32 48 56 69 97 65
  Korean 7 17 8 19 11 12
  SE Asian 3 4 11 15 22 16
  Other Asian 4 2 2
 NHOPI 9(10.6) 15(9.4) 38 (16.2) 60(17.6) 78 (17.4) 59 (15.4)
 White 11(12.9) 24 (15.1) 43 (18.4) 77(22.6) 102(22.8) 94 (24.5)
 Hispanic 0 2 (1.3) 3(1.3) 6 (1.8) 11 (2.5) 14 (3.6)
 Mixed 0 0 1 (0.4) 9 (2.6) 23 (5.1) 34 (8.9)
 Other 0 1(0.6) 1 (0.4) 2 (0.6) 9(1.3) 2 (0.6)
Birthplace
 United States 36(42.4) 79(49.7) 138(59) 207(60.7) 299(66.7) 234(60.9)
 Asia 24(24.7) 58(36.5) 77(32.9) 101(29.6) 103(23) 106(27.6)
 Pacific Island 3(3.5) 6(3.8) 16 (6.8) 23 (6.7) 25 (5.6) 27 (7.0)
Public Medical Insurance 37 (43.5) 74 (46.5) 108 (46.2) 166 (48.7) 261 (58.3) 241 (62.8)
Completed high school - - 117 (50%) 234 (68.6) 335(74.8) 309 (80.5)

SE Asian : Southeast Asian

NHOPI; Native Hawaiian/Other Pacific Islander

all characteristics listed as number (%)

There is a decreasing proportion of HCC cases related to viral hepatitis B. The cases related to hepatitis C peaked in 2013 to 2017 and have since decreased. The proportion of patients with significant alcohol use has persisted and has not changed significantly by era. (Figure 2) The HCC cases related to MASLD, diabetes and hyperlipidemia however have markedly increased and currently comprise about 28.6% of all cases. (table 1). There were significant differences in mean BMI and distribution of weight classes over time. (table 3)

Figure 2: Risk factors by era.

Figure 2:

Patients with various risk factor by era. HCV p=0.0003; HBV p<0.0001; alcohol p=0.4984; obesity p<0.0001; MASH/FLD <0.0001; diabetes p<0.0001; hyperlipidemia <0.0001generated using the Cochran-Mantel-Haenszel tests:

Table 3:

Weight/Obesity trends over time in patients with hepatocellular carcinoma

Era 1
(1993–1997)
Era 2
(1998–2002)
Era 3
(2003–2007)
Era 4
(2008–2012)
Era 5
(2013–2017)
Era 6
(2018–2022)
P valuea

Mean BMI (SD) 24.8(4.4) 25.9(5.4) 26.6(5.2) 27(5.4) 27.3(5.8) 28.3(12.3) 0.0053
Underweight (BMI<18.5) 3 (6.4%) 4 (4.2%) 6 (3.1%) 6 (1.8%) 15 (3.4%) 9 (2.3%) <.0001
Normal weight (BMI 18.5–29.9) 39 (83.0%) 78 (81.3%) 146 (76.0%) 255 (75.2%) 313 (70.2%) 271 (70.6%)
Obese (BMI 30–35) 4 (8.5%) 9 (9.4%) 29 (15.1%) 49 (14.5%) 68 (15.2%) 62 (16.1%)
Morbidly obese (BMI>35) 1 (2.1%) 5 (5.2%) 11 (5.7%) 29 (8.6%) 50 (11.2%) 42 (10.9%)
Obesity/Morbid Obesity 5 (10.6%) 14 (14.6%) 40 (20.8%) 78 (23.0%) 122 (27.4%) 105 (27.3%)
a

Cochran-Mantel-Haenszel tests or generalized linear models

Tumor characteristics and underlying liver disease have also changed over time. Over the eras, an increasing proportion of patients were found with HCC surveillance and with stage I disease. About 65–78% of patients had underlying cirrhosis, however, a slightly smaller proportion had a screenable disease in the more recent eras. While AFP is generally a part of HCC surveillance, it was found to be less likely to be elevated in the more recent eras, with over half of the patients having a normal AFP at the time of their HCC diagnosis. (table 4)

Table 4;

Tumor and underlying liver characteristics by era

Era 1
(1993–1997)
Era 2
(1998–2002)
Era 3
(2003–2007)
Era 4
(2008–2012)
Era 5
(2013–2017)
Era 6
(2018–2022)
P valueb

#patients 85 159 234 341 448 384
AJCC stage 1 (%) 45 (52.9) 83 (52.2) 141 (60.3) 188 (55.1) 273 (60.9) 264 (68.8) <0.0001
Cirrhosis (%) 54 (63.5) 123 (77.4) 184 (78.6) 233 (68.3) 294 (65.6) 280 (72.9) 0.0057
Screenable disease (%) 67 (78.8) 133 (83.6) 192 (82.1) 268 (78.6) 291(65) 282 (73.4) <0.0001
HCC found with surveillance* (%) 15 (22.4) 16 (12.0) 20 (10.4) 109 (40.7) 148 (49.1) 147 (51.1) <0.001
Normal AFP (%) 21 (24.7) 55 (34.6) 76 (32.5) 140 (41.4) 199 (44.4) 203 (52.9) <0.001
*

based on patients who had a screenable disease.

b

Cochran-Mantel-Haenszel tests or generalized linear models

There were notable differences in survival by era (Figure 3). By Cox Regression, the highest predictor for survival included having a liver transplant (HR 3.39 (95% CI 2.46–4.67), p<0.0001). Other predictors included the more recent eras; Era 4 (HR 1.71 (95%CI 1.23–2.36, p=0.0013), Era 5 (HR 2.40 (95% CI 1.73–3.33), p<0.0001) and Era 6 (HR 2.26 (95% CI 1.59–3.22), p<0.001). AJCC stage 1 (HR 1.52 (95%CI; 1.30–177), p<0.0001) and age ≥ 60 yrs (HR 1.24 (95%CI 1.05–1.46), p=0.01). Negative predictors of survival included diabetes (HR 0.74 (95% CI 0.62–0.87), p=0.0002) and MASLD (HR 0.77 (95% CI; 0.59–0.99, p=0.4). Sex, cirrhosis, obesity, hepatitis B, hepatitis C, alcohol use and smoking were not predictive of year survival.

Figure 3; Survival by Era.

Figure 3;

Kaplan Meier survival curves by Era

Discussion

Hawaii had a high incidence of HCC in the past presumably because of its large number of Asian and NHOPI residents. However, the demographics in Hawaii has continued to change, potentially affecting the profile of HCC cases encountered over time. Hawaii currently has the highest racial and ethnic diversity in the US with 56% of the population who are either Asian alone or Asian in combination with another race, 25% White and 10.3% who are NHOPI. More recently, Hispanics are amongst the fasting growing population in Hawaii and now compromise 11.1% of the population. (RRID:SCR_011587) Currently, in the US, Asians and NHOPI have a higher than average incidence and death rate of HCC with Asian/NHOPI males having an incidence of 18.2 per 100,000 and death rate of 17.3 per 100,000 compared to all males at with incidence of 14.1 per 100,000 and death rate of 9.6 per 100,000. However, Hispanic males have an incidence of 26.8 and a death rate of 13.1/100,000. (13) Our data clearly reflects this trend, as in the 1990s, about 80% of the cases were occurring in Asians and NHOPI but currently HCC while still occurring in Asians, is affecting all races and more prominently in Whites and Hispanics than previous. MASLD initially only was responsible for 3.5% of patients in era 1 whereas it has increased to 28.6% in era 6 – a nearly 10-fold increase over 30 years.

In this study, we examined birthplace as a factor affecting HCC in Hawaii. In the US in 2022, approximately 13.9% of the US population was born in a foreign country and while not as high as California or New York, Hawaii had 17.1% of its residents born outside the US. (14) The prevalence of viral hepatitis certainly varies by birthplace and the Surveillance, Epidemiology and End-Results (SEER) data suggest that birth country was associated with the age at HCC diagnosis with those born in Oceania having a very early onset of HCC. (15) Consistent with this, our previous studies showed that Pacific Islanders born outside the US were younger at diagnosis of HCC and more likely to have hepatitis B. (8) In this study, about a third of HCC patients were born outside the US and while this proportion varied slightly from era to era, there is not any trend to suggest that it is increasing or decreasing. However, while there has been a large number of Pacific Islanders born in Pacific Island nations with HCC in recent eras, there also appears to be an increase in HCC among US-born. One potential explanation for this trend is the rising incidence of diabetes, obesity, and other metabolic conditions that contribute to MASLD, which, as reported in this study, comprise the fastest growing risk factors for HCC in Hawaii in recent years.

Historically, the incidence of Hepatitis B has been higher in Hawaii compared to the rest of the United Status. A mass screening of 3989 people in Hawaii from 2003–2006 for hepatitis B demonstrated a 3.6% seroprevalence which was much higher than the US population, with Pacific Islanders 7.47 times more likely to have hepatitis B when compared to Whites. (16) However, 20 years later, it was reported that hepatitis B-associated deaths have decreased in both the general population and the non-Hispanic Asians/Pacific Islanders. Hepatitis B associated mortality decreased from 1.83 to 1.22 per 100,000 population from 2012–2014 to 2018–2020 (17). In our study, the absolute number of HCC cases with hepatitis B as a contributing factor seem to persist over time, however the proportion of patients is smaller, potentially because there are so many more patients with MASLD-related HCC. Despite the worldwide adoption of the hepatitis B vaccine, there continues to be hepatitis B related complications and HCC in Hawaii. This may be due to the limited availability of the hepatitis B vaccine in remote Pacific Island nations and inconsistent vaccination in some of our older Asian immigrants.

While there are very effective treatments for hepatitis C with the direct acting antiviral medications (DAAs), there are an estimated 50 million people worldwide who are living with hepatitis C. (18) In 2020, there were 107,3000 newly diagnosed cases of chronic hepatitis C reported however the age adjusted death rate for hepatitis C decreased 22% from 2016. (19) The Global Burden of Diseases which has data on 204 countries between 1990 and 2019 demonstrated that HCV related chronic liver disease deaths surpassed those from HBV. South Asian and East Asia are predicted to have the highest number of chronic liver disease deaths related to HCV and HBV by 2030. None of the 204 countries is projected to achieve the WHO target of a 65% reduction in mortality from HBV and HCV by 2030. (20) The burden of HCV related HCC has steadily increased but several studies have suggested a stable to slight decrease in the more recent years. (21–24) Globally, there are regional variations in HCV related HCC mortality between 1999 to 2018. East Asia and Pacific regions having a decline in mortality and North America with a rise in mortality. (25) In our study, there was a steady increase in HCV related HCC up until 2018 when the number of cases decreased. However, the proportion of cases seems considerably less due to the increased proportion of MASLD related HCC.

The epidemic of obesity along with metabolic complications of diabetes and hyperlipidemia have contributed to a global prevalence of MASLD affecting approximately 30% of the population. (26) There are regional variations with the highest prevalence in South America where it is estimated to about 59% of their population. In North America the prevalence is 56.7% with the highest prevalence in Hispanic. (27–30) Liver transplantation for Metabolic Associated steatohepatitis (MASH) is increasing and is currently the second highest reason for liver transplantation in the US. (31) Approximately 1–3% of patients per year with MASLD-related cirrhosis will develop HCC and surveillance for this may be justified. (31.32) Mathematical models predict that HCC cases will increase in the US by 122% from 2016 to 2030. (33) Our study clearly reflects these national and global trends with less MASLD-related HCC in the early eras and currently accounting for 28.6% of HCC cases in the most recent era. Over 50% of our most recent patients have hyperlipidemia and 44% have diabetes. There are also metabolic comorbidities coexisting in patients with viral hepatitis B and C which may contribute to the pathogenesis of HCC.

This study is limited in that it is a single center report and may not be representative of the entire population of HCC in the state of Hawaii. While we had information on various risk factors, we did not have information on the duration of time that patients had these risk factors – especially the metabolic risk factors. We also did not have consistent details on cholesterol, triglycerides, glucose control or waist to hip ratios which would better characterize the metabolic associated steatohepatitis. Finally, we also may have underestimated the influence of obesity as the WHO definition of obesity in Asians is based on a lower BMI and our population had a large proportion of Asians. We also were unable to accurately estimate the impact of ascites on the BMI.

Despite these limitations, this is a large study on nearly 70% of HCC in Hawaii and we had considerable granularity on many details that would not be available in typical administrative or cancer specific databases. We have shown that traditional risk factors for HCC in Hawaii including viral hepatitis B persist despite the use of hepatitis B vaccines and antivirals agents. However, the persistently high incidence of HCC in Hawaii may be more influenced by metabolic risk factors and the changing demographics of the state. While Hawaii has made tremendous efforts to identify viral hepatitis in high-risk and vulnerable populations and to provide subsequent linkage to care, future efforts should also concentrate on addressing metabolic risk factors. Our survival has clearly improved over time, but more efforts should target community education to promote weight management and exercise as well primary care provider education on the need for appropriate management of diabetes, obesity and hyperlipidemia as well as recognition of steatotic liver disease and timely referral to liver specialists.

Acknowledgement

This study was presented at a poster at the Asia Pacific Primary Liver Experts Annual meeting July 6–8, 2023 in Seoul, Korea.

Funding:

BY Hernandez is the recipient of a grant from National Institutes of Health grant U01CA284379

Footnotes

Conflict of Interest

Dr Wong is a speaker for Astra-Zeneca. Dr Acoba receives research funding from Glaxo Smith Kline.

All other authors have no conflicts of interest.

References

  • 1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. [DOI] [PubMed] [Google Scholar]
  • 2.Cancer Stat Facts: Liver and intrahepatic Bile Duct cancer, https://seer.cancer.gov/statfacts/html/livibd.html (accessed January 16, 2025)
  • 3.Nasereldin DS, White LJ, Hodge DO, Roberts LR, Patel T, Antwi SO. Association of metabolic health phenotypes, obesity and hepatocellular carcinoma risk. Dig Liver disease. 2022;54:964–972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ochner M, Wong LL, Wimmer-Kunitomo K. Hepatocellular cancer: risk factors and survival in Pacific Islanders compared to Caucasians, in Hawaii. Ethnicity and Disease 2010;20:169–173. [PubMed] [Google Scholar]
  • 5.Wong LL, Tsai N. Hepatocellular Carcinoma in Filipinos. Asia-Pacific Journal of Clinical Oncology. 2007;3:44–48. [Google Scholar]
  • 6.Wu EM, Hernandez BY, Wong LL. Hepatocellular carcinoma in Micronesians, a growing Pacific Islander population in the U.S. Open J of Gastroenterology. 2018;8:223–233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wong LL, Hernandez B, Kwee S, Albright C, Okimoto G, Tsai N. Healthcare Disparities in Asians and Pacific Islanders with hepatocellular cancer. American Journal of Surgery. 2012;203: 726–32 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yee S, Kwee SA, Hernandez B, Wong LL. Hepatocellular Carcinoma in Pacific Islanders: Comparison of Pacific Island-born vs US-born. Hepatoma Research. 2023:9;7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wong LL, Ogihara M, Ji J, Tsai N. The Changing Characteristics of Hepatocellular Cancer Over Time. American Journal of Surgery. 2015;210:146–52. [DOI] [PubMed] [Google Scholar]
  • 10.Singal AG, Llovet JM, Yarchoan M. Mehta N, Heimbach JK, Dawson LA et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922–1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology. 2015;61:1056–1065. [DOI] [PubMed] [Google Scholar]
  • 12.Rinella ME, Lazarus JV, Ratziu V, Francque SM, SAnyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023:29; 1–15. [DOI] [PubMed] [Google Scholar]
  • 13.Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute; Surveillance, Epidemiology and End Results Program. [Cited 2024 July4] Available at;] https://seer.cancer.gov/statfacts/html/livibd.html,. [Google Scholar]
  • 14.Statista; Percentage of foreign-born population in the United States in 2023, by state. [Cited 2024 July4] Available at: https://www.statista.com/statistics/312701/percentage-of-population-foreign-born-in-the-us-by-state/
  • 15.Yang JD, Altekruse S, Nguyen M, Gores GH, Roberts LR. Impact of Country of Birth on the Age of Diagnosis of Hepatocellular Carcinoma in the United States. Cancer. 2017;123: 81–89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tsai N, Holck PS, Wong LL, Ricalde AA. Seroepidemiolology of Hepatitis B virus infection: analysis of mass screening in Hawaii. Hepatol Int. 2008;2:478–485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Rahberg N, Li F, Goto R, Pham T. Trends and Patterns of Hepatitis B associated deaths in Hawaii 2000–2020. Hawaii Journal of Health and Social Welfare. 2023;82:19–24. [PMC free article] [PubMed] [Google Scholar]
  • 18.World Health Organization. The Global Health Observatory. Hepatitis at https://www.who.int/data/gho/data/themes/chronic-viral-hepatitis. Accessed January 15, 2025.
  • 19.Center for Disease Control; Viral Hepatitis: Hepatitis C Surveillance 2020. [Cited 2024 Jul4] Available at; https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c.htm,.
  • 20.Ou TY, Huy LD, Mayne J, Shih CL, Xuan HM, Nguyen NTH, et al. Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030. J Infect Public Health. 2024;17:102443. [DOI] [PubMed] [Google Scholar]
  • 21.Pinheiro PS, Jones PD, Medina H, Cranford HM, Koru-Sengul T, Bungum T, et al. Incidence of Etiology-specific Hepatocellular Carcinoma: Diverging Trends and Significant Heterogeneity by Race and Ethnicity. Clin Gastroenterol Hepatol. 2024;22:562–571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chandran V, Rajandran A, Loo KF, Bate J, Wigg A, Chinnaratha MA. Hepatocellular carcinoma (HCC) is changing its face: analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia Intern Med J. 2023;53:1131–1136. [DOI] [PubMed] [Google Scholar]
  • 23.Innes H, McDonald SA, Hamill V, Yeung A, Dillon JF, Hayes PC, et al. Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: A population-based cohort study. Liver Int. 2022;42:561–574. [DOI] [PubMed] [Google Scholar]
  • 24.Fouad Y, Gaber Y, Abdel Alem S, Abdallah M, Abd-Elsalam SM, Nafady S, et al. Changes in the Etiologies of Liver Cancer in Upper Egypt over a Decade from 2010 to 2020: A Single Tertiary Care Center Study. South Asian J Cancer. 2023;3;13:10–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ali H, Vikash F, Moond V, Khalid F, Jamil AR, Dahiya DS, et al. Global trends in hepatitis C-related hepatocellular carcinoma mortality: A public database analysis (1999–2019). World J Virol. 2024;25;13:89469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Teng ML Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2023;29: S32–S42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Le MJ, Le DM, Baez TC, Wu Y, Ito T, Lee EY, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J. Hepatol. 2023;79:287–295. [DOI] [PubMed] [Google Scholar]
  • 28.Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023;7:851–861. [DOI] [PubMed] [Google Scholar]
  • 29.Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–398. [DOI] [PubMed] [Google Scholar]
  • 30.Scientific Registry of Transplant Recipients, OPTN/SRTR 2022 Annual Data Report: Liver. [Cited 2024 Jul5] Available at: https://srtr.transplant.hrsa.gov/ADR/Chapter?name=Liver&year=2022
  • 31.Loomba R, Lim JK. Patton H. El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2023;158:1822–1830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis M, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–750. [DOI] [PubMed] [Google Scholar]
  • 33.Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Cabelleria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Hepatol. 2018; 69: 896–904 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data generated in this study are not publicly available as information could compromise patient privacy as it contains sensitive information and coming from a small area. However portions of the data that do not include specific dates or protected health information can be available upon reasonable request from the corresponding author.

RESOURCES